Literature DB >> 9850487

The U.K. Prospective Diabetes Study. A review.

R C Turner1.   

Abstract

The objective of the U.K. Prospective Diabetes Study (UKPDS), initiated in 1977, was set up to determine whether improved blood glucose control in people with type 2 diabetes will prevent the complications of diabetes. The UKPDS was also designed to determine whether there are differences between conventional policy (diet therapy) and three different regimens of intensive treatment policy, based on sulfonylurea, metformin, or insulin. Interim efficacy analyses revealed that the intensive policies with sulfonylurea, insulin, and metformin were equally effective in reducing fasting plasma glucose concentrations. However, glucose and HbA1c measurements steadily increased with time, reflecting ongoing deterioration of beta-cell function. Cardiovascular disease was the major cause of complications, and the risk factors included raised LDL cholesterol concentrations, low HDL cholesterol concentrations, elevated blood pressure, elevated HbA1c concentrations, and smoking. A final study report was issued in September 1998, when the median duration of therapy was 11 years.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850487     DOI: 10.2337/diacare.21.3.c35

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  48 in total

Review 1.  The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study.

Authors:  R M Ewart
Journal:  BMJ       Date:  2001-10-13

Review 2.  Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus.

Authors:  Yuji Kadoi
Journal:  J Anesth       Date:  2010-07-17       Impact factor: 2.078

Review 3.  The impact of evidence-based medicine on diabetes therapy.

Authors:  Phillip Gorden; Carla Musso
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

4.  The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity.

Authors:  Fabrice M A C Martens; Frank L J Visseren
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 4.810

5.  Sitagliptin: a viewpoint by Itamar Raz.

Authors:  Itamar Raz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Looking beyond overnutrition for causes of epidemic metabolic disease.

Authors:  Leonid Poretsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-14       Impact factor: 11.205

7.  Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.

Authors:  K Aston-Mourney; R L Hull; S Zraika; J Udayasankar; S L Subramanian; S E Kahn
Journal:  Diabetologia       Date:  2011-04-12       Impact factor: 10.122

Review 8.  Prandial hyperglycemia: is it important to track and treat?

Authors:  Markolf Hanefeld; Frank Schaper
Journal:  Curr Diab Rep       Date:  2005-10       Impact factor: 4.810

9.  PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago.

Authors:  Steve Ian Smith
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Authors:  B Charbonnel; G Schernthaner; P Brunetti; D R Matthews; R Urquhart; M H Tan; M Hanefeld
Journal:  Diabetologia       Date:  2005-05-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.